Alzamend Neuro公司AL001实现总锂血液暴露量达101%,峰值水平较标准碳酸锂高出97%

美股速递
Mar 26

Alzamend Neuro公司宣布,其研发的AL001在关键指标上表现出显著优势。与标准碳酸锂制剂相比,AL001实现了总锂血液暴露量达到101%的优异结果。同时,其血液中的峰值锂水平也比标准碳酸锂高出97%。

这一数据突显了AL001在药物递送效率和生物利用度方面的潜在突破,为阿尔茨海默病及相关神经系统疾病的治疗带来了新的希望。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10